Semaglutide and Glimepiride Demonstrate Positive Cardiovascular Risk Outcomes in Recent Clinical Trials

Compiled by: Fan Dongdong

The 79th Scientific Sessions of the American Diabetes Association (ADA) kicked off this week, drawing nearly 15,000 industry representatives from around the globe to share the latest research findings, treatment recommendations, and academic advancements in diabetes care. According to statistics, the conference will feature approximately 8,750 presentations and 2,000 original research reports. Two days ago, we compiled some of the latest research results; today, Sina Medicine continues to highlight other key takeaways as follows:

· Semaglutide Reduces Cardiovascular Mortality and All-Cause Mortality by Nearly 50%

Novo Nordisk Presents PIONEER 6 Trial Data. The trial enrolled 3,183 patients across 21 countries, who were randomized into two groups to receive either oral semaglutide at a dose of 14 mg once daily or placebo. Data from a median follow-up of 15.9 months showed that oral semaglutide reduced cardiovascular mortality and all-cause mortality by nearly 50%.

·Primary Endpoint of the Glimepiride Study

Boehringer Ingelheim and Eli Lilly Announce CAROLINA Trial Data. The trial found that glimepiride and Tradjenta (linagliptin) had similar effects on cardiovascular morbidity and mortality in patients with early type 2 diabetes over a median follow-up of 6.3 years, meeting the study’s primary endpoint. The study also found that Ozempic was safe in patients with type 2 diabetes at high cardiovascular risk and demonstrated non-inferiority to glimepiride.

· VeroScience Conducted Six Preclinical Studies on Metabolic Diseases

The metabolic diseases involved in the study include obesity, prediabetes, type 2 diabetes, and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. The company’s therapeutic approach employs circadian neuroendocrine reset therapy, a biochemical and physiological method that recalibrates lifestyle-induced circadian rhythm disruptions, such as those caused by high-fat/high-sugar diets, psychosocial stress, and alterations in sleep/wake patterns.

· Patients with type 1 diabetes and higher blood pressure levels have a higher risk of developing CAD.

Researchers from the University of Pittsburgh’s Center for Medication Policy and Prescribing conducted a study on 605 patients with type 1 diabetes who were diagnosed before the age of 17, with a follow-up period of 25 years. The primary finding was that patients with blood pressure levels ≥120/80 mmHg were twice as likely to develop coronary artery disease (CAD) compared to those with lower blood pressure.

· Immunotherapy May Delay Onset of Type 1 Diabetes in Relatives of Patients

Yale University researchers published study findings from a trial designed to investigate why relatives of patients with type 1 diabetes are at higher risk of developing the disease and whether immunotherapy could delay its onset. The study enrolled a total of 76 participants, including 55 individuals aged over 18 years. Participants were assigned to receive either teplizumab (an FcR-nonbinding humanized monoclonal anti-CD3 antibody) from Provention Bio or a placebo. Two participants withdrew during the trial, and ultimately 42 were diagnosed with type 1 diabetes. The proportion diagnosed with type 1 diabetes was 72% in the placebo group and 43% in the teplizumab treatment group.

Reference Source: ADA Spotlight: Novo Nordisk, Boehringer Ingelheim, Eli Lilly and More